Since the delivery of our first ultra-widefield device in 2000, Optos has continued to gather clinical evidence about the importance of seeing the peripheral retina especially in patients with diabetes. optomap is the only ultra-widefield retinal imaging technology that captures up to 200° of the retina in a single image.
-
optomap is clinically validated and supported by over 550 completed and ongoing clinical studies.
-
optomap results are equal to ETDRS in all categories.1
-
optomap imaging demonstrates that diabetic lesions that occur outside of the ETDRS 7 standard fields predict increased risk of diabetic retinopathy progression over a 4 year period. 2
-
Ultra-widefield retinal evaluation provides information that is necessary to completely assess the risk of DR progression.3
1,2,3 - Data on file